<i>Candida lusitaniae</i> arthritis in an intravenous drug user

Jeragh, A.; Ahmad, Sayeed; Naseem, J.; Khan, ZU

doi:10.1111/j.1439-0507.2007.01394.x

Cited by 15 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limited data suggest that positive predictive values of β-D-glucan in bronchoalveolar lavage fluid are poor for diagnosing fungal pneumonia [159]. There are case reports for testing of samples collected from other sites of invasive Candida infection [160].…”

Section: Antigen and Antibody Detectionmentioning

confidence: 99%

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

Pappas

Kauffman

Andes

et al. 2015

Clinical Infectious Diseases

2,685

2,708

View full text Add to dashboard Cite

It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.

show abstract

Section: Antigen and Antibody Detectionmentioning

confidence: 99%

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

Pappas

Kauffman

Andes

et al. 2015

Clinical Infectious Diseases

2,685

2,708

View full text Add to dashboard Cite

show abstract

“…In a recent case report of a patient with Candida lusitaniae joint infection, beta-glucan testing demonstrated high concentrations corresponding to the positive cultures. 28 Studies in rabbits infected with Candida albicans to create an experimental model for hematogenous candidal meningoencephalitis found that 100% of the animals had demonstratable levels of beta-glucan in the cerebrospinal fluid. 29 In animals cleared of the infection, levels of betaglucan in the cerebrospinal fluid decreased as a marker for response to therapy.…”

Section: Therapeutic Monitoringmentioning

confidence: 99%

(1–3)-β-D-Glucan Assay: A Review of its Laboratory and Clinical Application

Wright

Overman

Ribes

2011

Lab Med

View full text Add to dashboard Cite

A new fungal surrogate marker, (1-3)-β-D glucan, offers a noninvasive method for the potential surveillance and diagnosis of invasive fungal infections. Invasive fungal infections have long been associated with significantly high morbidity and mortality on hematology-oncology wards and recipients of either solid-organ or hematopoietic stem cell transplantation. The diagnoses of invasive fungal infections have historically been made difficult by the need for invasive methods.(1-3)-β-D-glucan testing requires a minimally invasive sample that can be used to aid in the diagnosis of an invasive fungal infection as well as monitor the response to treatment. One disadvantage of (1-3)-β-D-glucan testing is that a positive test alone lacks sufficient sensitivity and specificity for a definitive diagnosis. While formal guidelines for the use of (1-3)-β-D-glucan testing are lacking, this chromogenic assay provides a new opportunity for testing at-risk populations. A review and recommendation for its laboratory and clinical application are provided. Glossary(1-3)-β-D-glucan: A polysaccharide component of the cell wall of most fungi pyrogen test. An assay used to determine if a pharmaceutical or medical device intended for human use will stimulate fever.Keywords: (1-3)-β-D glucan, beta glucan assay, invasive fungal infections After reading this article, readers should be able to discuss what (1-3)-β-D glucans are, how they are detected in clinical biological samples, the evidence to support laboratory testing and monitoring, the limitations of testing, and the appropriate clinical setting for testing.Microbiology 71103 questions and corresponding answer form are located after this CE Update on page 686.

show abstract

“…In Kuwait, little information is available on the association of C . lusitaniae with human colonization and infection [14]. This study describes prevalence and susceptibility profile of clinical isolates of C .…”

Section: Introductionmentioning

confidence: 99%

Candida lusitaniae in Kuwait: Prevalence, antifungal susceptibility and role in neonatal fungemia

et al. 2019

View full text Add to dashboard Cite

Objectives Candida lusitaniae is an opportunistic yeast pathogen in certain high-risk patient populations/cohorts. The species exhibits an unusual antifungal susceptibility profile with tendency to acquire rapid resistance. Here, we describe prevalence of C . lusitaniae in clinical specimens in Kuwait, its antifungal susceptibility profile and role in neonatal fungemia. Methods Clinical C . lusitaniae isolates recovered from diverse specimens during 2011 to 2017 were retrospectively analyzed. All isolates were identified by germ tube test, growth on CHROMagar Candida and by Vitek 2 yeast identification system. A simple species-specific PCR assay was developed and results were confirmed by PCR-sequencing of ITS region of rDNA. Antifungal susceptibility was determined by Etest. Minimum inhibitory concentrations (MICs) were recorded after 24 h incubation at 35°C. Results Of 7068 yeast isolates, 134 (1.89%) were identified as C . lusitaniae including 25 (2.52%) among 990 bloodstream isolates. Species-specific PCR and PCR-sequencing of rDNA confirmed identification. Of 11 cases of neonatal candidemia, 9 occurred in NICU of Hospital A and are described here. Eight of 9 neonates received liposomal amphotericin B, which was followed by fluconazole in 7 and additionally by caspofungin in 2 cases as salvage therapy. Three of 8 (37.5%) patients died. No isolate exhibited reduced susceptibility to amphotericin B, fluconazole, voriconazole, caspopfungin, micafungin and anidulafungin. The MIC ± geometric mean values for amphotericin B, fluconazole, voriconazole, and caspofungin were as follows: 0.072 ± 0.037 μg/ml, 2.32 ± 0.49 μg/ml, 0.09 ± 0.01 μg/ml and 0.16 ± 0.08 μg /ml, respectively. Only two isolates exhibited reduced susceptibility to fluconazole. Conclusions This study describes the prevalence and antifungal susceptibility profile of clinical C . lusitaniae isolates in Kuwait. No isolate showed reduced susceptibility to amphotericin B. The study highlights the emerging role of C . lusitaniae as a healthcare-associated pathogen capable of causing fungemia in preterm neonates and causing significant mortality.

show abstract

Candida lusitaniae arthritis in an intravenous drug user

Cited by 15 publications

References 0 publications

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

(1–3)-β-D-Glucan Assay: A Review of its Laboratory and Clinical Application

Candida lusitaniae in Kuwait: Prevalence, antifungal susceptibility and role in neonatal fungemia

Contact Info

Product

Resources

About